The University of Southampton
University of Southampton Institutional Repository

Molecular targeting of lymphoma through bromodomain inhibition and induction of apoptosis

Molecular targeting of lymphoma through bromodomain inhibition and induction of apoptosis
Molecular targeting of lymphoma through bromodomain inhibition and induction of apoptosis
Diffuse large B-cell lymphoma (DLBCL) is a common cancer, with an annual incidence in the UK of approximately 5000. About 40% of patients fail first-line therapy, these refractory or relapsed (R/R) patients have a poor prognosis. A closely related cancer, Burkitt lymphoma (BL) exhibits higher cure rates but requires regimens with high toxicity to achieve this. Both frequently exhibit oncogenic MYC dysregulation, which is closely linked to apoptosis activation in healthy cells. This connection must be broken for malignant cells to develop and thrive. Targeting this relationship was an approach we employed to explore novel therapies for lymphomas. We employed novel bromodomain and extraterminal (BET) inhibitors, PLX51107 and PLX2853, in Eμ-myc lymphoma cells and human lymphoma cells to induce apoptosis. We determined that this was largely through BIM upregulation, a key pro-apoptotic protein. We concluded that this was largely mediated through downregulation of a micro RNA cluster miR-17/92, which is a target of MYC implicated in oncogenesis. High expression of pro-survival BCL-2 protein is associated with worse outcomes in DLBCL and is known to inhibit BIM. We were able to show that by inhibiting BCL-2 with a BH3-mimetic (ABT- 199) we could resensitise cells with high expression of BCL-2 to BET inhibition. This was seen in murine lymphomas manipulated to upregulate BCL-2, and human lymphomas with high BCL-2 expression both in vitro and in vivo. The combination effect was demonstrated to be synergistic in DLBCL cell lines. It co-incided with increased binding of BIM to BCL-2, priming the cells for death. We further confirmed that alternative BH3-mimetics targeting alternative BCL-2 prosurvival family members (BCL-XL and MCL-1) could combine with BET inhibitors to increase apoptosis in lymphoma. Finally, we examined a large dataset of gene expression from a phase III clinical trial in DLBCL, REMoDL-B. This identified that high expression of BCL-2 mRNA, as well as BCL-XL mRNA were associated with worse progression free survival in DLBCL cell of origin subtypes. It is clear that BCL-2 family members contribute to treatment resistance in DLBCL. We demonstrated a novel approach to overcome this by using small molecule inhibitors to upregulate a pro-apoptotic protein (BIM) with concurrent anti-apoptotic protein inhibition (BCL-2, BCL-XL, MCL-1) to result in lymphoma cell demise. Future clinical trials can be guided to improve patient survival by identifying such treatment-resistance mechanisms and over-coming them through combination evidence-based therapy design based on pre-clinical studies.
University of Southampton
Cummin, Thomas Edward Comyn
510fcba1-9f8d-4382-99a5-4c4261b9d0f4
Cummin, Thomas Edward Comyn
510fcba1-9f8d-4382-99a5-4c4261b9d0f4
Cragg, Mark
ec97f80e-f3c8-49b7-a960-20dff648b78c

Cummin, Thomas Edward Comyn (2022) Molecular targeting of lymphoma through bromodomain inhibition and induction of apoptosis. University of Southampton, Doctoral Thesis, 313pp.

Record type: Thesis (Doctoral)

Abstract

Diffuse large B-cell lymphoma (DLBCL) is a common cancer, with an annual incidence in the UK of approximately 5000. About 40% of patients fail first-line therapy, these refractory or relapsed (R/R) patients have a poor prognosis. A closely related cancer, Burkitt lymphoma (BL) exhibits higher cure rates but requires regimens with high toxicity to achieve this. Both frequently exhibit oncogenic MYC dysregulation, which is closely linked to apoptosis activation in healthy cells. This connection must be broken for malignant cells to develop and thrive. Targeting this relationship was an approach we employed to explore novel therapies for lymphomas. We employed novel bromodomain and extraterminal (BET) inhibitors, PLX51107 and PLX2853, in Eμ-myc lymphoma cells and human lymphoma cells to induce apoptosis. We determined that this was largely through BIM upregulation, a key pro-apoptotic protein. We concluded that this was largely mediated through downregulation of a micro RNA cluster miR-17/92, which is a target of MYC implicated in oncogenesis. High expression of pro-survival BCL-2 protein is associated with worse outcomes in DLBCL and is known to inhibit BIM. We were able to show that by inhibiting BCL-2 with a BH3-mimetic (ABT- 199) we could resensitise cells with high expression of BCL-2 to BET inhibition. This was seen in murine lymphomas manipulated to upregulate BCL-2, and human lymphomas with high BCL-2 expression both in vitro and in vivo. The combination effect was demonstrated to be synergistic in DLBCL cell lines. It co-incided with increased binding of BIM to BCL-2, priming the cells for death. We further confirmed that alternative BH3-mimetics targeting alternative BCL-2 prosurvival family members (BCL-XL and MCL-1) could combine with BET inhibitors to increase apoptosis in lymphoma. Finally, we examined a large dataset of gene expression from a phase III clinical trial in DLBCL, REMoDL-B. This identified that high expression of BCL-2 mRNA, as well as BCL-XL mRNA were associated with worse progression free survival in DLBCL cell of origin subtypes. It is clear that BCL-2 family members contribute to treatment resistance in DLBCL. We demonstrated a novel approach to overcome this by using small molecule inhibitors to upregulate a pro-apoptotic protein (BIM) with concurrent anti-apoptotic protein inhibition (BCL-2, BCL-XL, MCL-1) to result in lymphoma cell demise. Future clinical trials can be guided to improve patient survival by identifying such treatment-resistance mechanisms and over-coming them through combination evidence-based therapy design based on pre-clinical studies.

Text
Molecular Targeting of Lymphoma through Bromodomain Inhibition and Induction of Apoptosis - Version of Record
Available under License University of Southampton Thesis Licence.
Download (15MB)
Text
Permission to deposit thesis form (1)_TAN
Restricted to Repository staff only

More information

Submitted date: August 2021
Published date: 30 June 2022

Identifiers

Local EPrints ID: 475794
URI: http://eprints.soton.ac.uk/id/eprint/475794
PURE UUID: 4ae46aab-3ab4-433c-b250-56b295135683
ORCID for Mark Cragg: ORCID iD orcid.org/0000-0003-2077-089X

Catalogue record

Date deposited: 28 Mar 2023 18:19
Last modified: 17 Mar 2024 07:42

Export record

Contributors

Author: Thomas Edward Comyn Cummin
Thesis advisor: Mark Cragg ORCID iD

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×